IVRO (Invitro International) EBITDA: $0.08 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invitro International EBITDA?

Invitro International IVRO +1.33% EBITDA is $0.08 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Invitro International's EBITDA for the three months ended in Mar. 2026 was $0.02 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.08 Mil.

During the past 12 months, the average EBITDA Growth Rate of Invitro International was 42.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 9 years, the highest 3-Year average EBITDA Growth Rate of Invitro International was 18.10% per year. The lowest was -152.00% per year. And the median was 17.50% per year.

Invitro International's EBITDA per Share for the three months ended in Mar. 2026 was $0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

During the past 12 months, the average EBITDA per Share Growth Rate of Invitro International was 100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 9 years, the highest 3-Year average EBITDA per Share Growth Rate of Invitro International was 38.70% per year. The lowest was -67.00% per year. And the median was 34.80% per year.

Invitro International  (OTCPK:IVRO) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Invitro International EBITDA Related Terms


Invitro International EBITDA Historical Data

* Premium members only.

The historical data trend for Invitro International's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invitro International EBITDA Chart

Invitro International Annual Data
Trend Feb90 Feb91 Sep92 Sep93 Sep94 Sep95 Sep96 Sep24 Sep25
EBITDA
Get a 7-Day Free Trial Premium Member Only -4.30 -2.80 -1.80 0.07 0.09

Invitro International Quarterly Data
Sep94 Dec94 Mar95 Jun95 Sep95 Dec95 Mar96 Jun96 Sep96 Dec96 Mar97 Jun97 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.04 0.02 0.01 0.02

IVRO vs IDTA, PRPH, NSTM: EBITDA Comparison

For the Diagnostics & Research subindustry, Invitro International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitro International EV-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Invitro International's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Invitro International's EBITDA for the fiscal year that ended in Sep. 2025 is calculated as

Invitro International's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Sep. 2025, Invitro International's EBITDA was $0.09 Mil.

Invitro International's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Invitro International's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Invitro International's EBITDA was $0.02 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $0.08 Mil mean?
Invitro International (IVRO) has a EBITDA of $0.08 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Invitro International.
Is Invitro International's EBITDA too high?
Invitro International's current EBITDA is $0.08 Mil.
How does Invitro International's EBITDA compare to IDTA and PRPH?
Invitro International's EBITDA of $0.08 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Diagnostics & Research company?
A good EBITDA depends on the Medical Diagnostics & Research industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Invitro International. Invitro International's current EBITDA is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current EBITDA is $0.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Invitro International (IVRO), the current EBITDA is $0.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invitro International Business Description

Address 330 East Orangethorpe Avenue, Suite D, Placentia, CA, USA, 92870
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.